SequelSEC

AVENUE THERAPEUTICS, INC. ATXI

Pharmaceutical Preparations · CIK 0001644963 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$707.00K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

AVENUE THERAPEUTICS, INC. (ATXI) reported revenue of $0 and net income of -$690.00K for the fiscal year ended 2026-06-30. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from AVENUE THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

AVENUE THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-12-312025-09-302025-06-302024-12-312024-09-302024-06-30
Revenue$0$0$0$1.40M$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$707.00K-$752.00K-$724.00K$297.00K-$1.60M-$3.16M-$2.82M
Net income-$690.00K-$709.00K-$683.00K$335.00K-$1.54M-$3.08M-$2.69M
Research & development$247.00K$257.00K$177.00K$192.00K$565.00K$2.33M$1.36M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$460.00K$698.00K$547.00K$915.00K$1.03M$829.00K$1.46M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

AVENUE THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-12-312025-09-302025-06-302024-12-312024-09-302024-06-30
Cash & equivalents$1.94M$2.86M$3.71M$3.33M$2.59M$2.60M$4.92M
Total assets$1.98M$2.93M$3.72M$4.16M$2.67M$2.62M$4.99M
Current assetsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total liabilities$1.41M$1.10M$1.42M$1.33M$816.00K$973.00K$1.16M
Current liabilities$1.41M$1.10M$1.42M$1.33M$816.00K$973.00K$1.16M
Total equity incl. NCI$569.00K$1.83M$2.30M$2.83M$1.86M$1.65M$3.83M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable$155.00KUnavailableUnavailable

Cash flow

AVENUE THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-12-312025-09-302025-06-302024-12-312024-09-302024-06-30
Operating cash flowUnavailable-$854.00K$383.00KUnavailable-$764.00K-$2.89MUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailable$0$0Unavailable
Financing cash flowUnavailable$0$0Unavailable$761.00K$567.00KUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailable$142.00K$163.00KUnavailable$522.00K$331.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

AVENUE THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-12-312025-09-302025-06-302024-12-312024-09-302024-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable21.2%UnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Revenue YoY growth-100.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable23.9%UnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable13.7%UnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATXI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.